AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Restoring baseline levels of miR-320a can slow disease progression by limiting phosphorylation of the PI3K/AKT pathway, downstream of BCR::ABL1, which reduces growth and survival of CML and has been shown to sensitize CML LSCs to IM [53,54].